Spero Therapeutics Reports Q3 2025 Financial Results

Tip Ranks
2025.11.13 22:49
portai
I'm PortAI, I can summarize articles.

Spero Therapeutics reported a Q3 2025 net loss of $7.4 million, a decrease from the previous year. The company highlighted Phase 3 trial results for tebipenem HBr, showing non-inferiority to IV treatments. GSK plans FDA submission in Q4 2025. Despite promising developments, Spero faces financial challenges, with a Hold rating and $4.00 price target on SPRO stock.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Spero Therapeutics ( (SPRO) ) has provided an update.

On November 13, 2025, Spero Therapeutics announced its third-quarter financial results and provided a business update. The company highlighted the Phase 3 PIVOT-PO trial results for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, which demonstrated non-inferiority to intravenous treatments. Spero’s partner, GSK, plans to submit these results to the FDA in the fourth quarter of 2025. The company reported a net loss of $7.4 million for the third quarter of 2025, a decrease from the previous year, and expects its current cash reserves to fund operations into 2028.

The most recent analyst rating on (SPRO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Spero Therapeutics stock, see the SPRO Stock Forecast page.

Spark’s Take on SPRO Stock

According to Spark, TipRanks’ AI Analyst, SPRO is a Neutral.

Spero Therapeutics is currently facing significant financial and operational challenges, as evidenced by declining revenues, negative profit margins, and operational inefficiencies. Technical analysis suggests ongoing bearish momentum, while valuation metrics highlight financial struggles due to a negative P/E ratio. The earnings call highlighted promising developments in their tebipenem HBr program, but these are offset by setbacks in other trials and increased financial losses. The overall score reflects these mixed but predominantly negative factors.

To see Spark’s full report on SPRO stock, click here.

More about Spero Therapeutics

Spero Therapeutics, based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company specializing in the development of novel treatments for rare diseases and multi-drug resistant bacterial infections.

Average Trading Volume: 643,076

Technical Sentiment Signal: Buy

Current Market Cap: $149.7M

Learn more about SPRO stock on TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer